Review and Interpretation of the 2018 ASCO Meeting

Review and Interpretation of the 2018 ASCO Meeting Banner


Date & Location
Saturday, July 21, 2018 7:00 AM - 4:15 PM   University Tower (HO) and Hine Hall (IP), Indianapolis, IN

Target Audience
Hematology/Oncology

Overview

This conference has been designed for hematologists, medical oncologists, oncology nurses, oncology pharmacists, and radiation oncologists. This program will provide participants with the latest information available as presented at the 2018 American Society of Clinical Oncology (ASCO) Meeting. Oncology/Hematology faculty members from the Indiana University School of Medicine (IUSM) will provide participants with analysis of the more clinically applicable presentations at this year's ASCO meeting.



Objectives

At the conclusion of this activity, participants should be able to:
  1. Recall and describe the newest developments in the treatment of a variety of cancers, including: Breast Cancer; Lung Cancer; Gastrointestinal Cancers, including colon, pancreas, gastric, esophageal, and hepatoma; Genito-Urinary Cancers, including prostate, bladder, kidney, and testicular cancer; Melanoma; Health Services Research; Phase I and Phase II Studies; Hematologic Malignancies, including multiple myeloma, leukemia, and lymphoma
  2. Integrate multimodality treatment strategies, including radiation therapy, chemotherapy, immunotherapy, and targeted therapy, into the management of patients with cancer
  3. Based on the most up-to-date treatments described in learning sessions, apply new knowledge about therapies of solid tumors and hematologic malignancies into their clinical practice
  4. Integrate the most up-to-date information on genomic analyses of cancer into their clinical practice

Registration

Registration Fees:

Free - IU Simon Cancer Center faculty, staff, nurses, fellows and residents-in-training
$50 - Non-IU nurses and other Non-IU (Non-Physician) Healthcare Providers
$150 - Physicians
$200 - Pharmaceutical Representatives



Accreditation
Continuing Medical Education Accreditation
The Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Indiana University School of Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Indiana University School of Medicine (IUSM) must demonstrate balance, independence, objectivity, and scientific rigor.  All faculty, authors, editors, and planning committee members participating in an IUSM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.  

The planning committee and those in a position to control the content of this activity have disclosed no relevant financial relationships, except for:
Gabriela Chiorean, MD disclosed she has received honoraria from AstraZeneca, Five Prime, Halozyme, Ipsen and Vicus Therapeutics.
Lawrence Einhorn, MD disclosed he owns stock in Amgen and Biogen Idec and is a paid advisory board member with Celgene.
Noah M. Hahn, MD disclosed he is a paid consultant for AstraZeneca, Bristol-Myers Squibb, Champions Oncology, Genentech, Incyte, Inovio, Merck and Company Inc., OncoGenex, Pieris, Principia, Rexahn, Seattle Genetics, Taris and Transmed.
Nasser Hanna, MD disclosed he has received research grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Shadia Jala, MD disclosed she has received a research grant from AstraZeneca.
Theodore Logan, MD disclosed he is a paid consultant for Prometheus. He also disclosed he receives research support from Abbott, Abraxis, Acceleron, Amgen, Argos, AstraZeneca, Aveo, Biovex, Bristol-Myers Squibb, Cerulean, Eisai, Eli Lilly, EMD Serono, GlaxoSmithKline, Hoffmann-LaRoche, Immatics, Macrogenics, Merck, Millenium, Novartis, Peloton, Pfizer, Prometheus, Roche, Synta, Threshold and Tracon.
Daniela Matei, MD disclosed she is a paid advisory board member for Clovis and Tesaro.
Kathy D. Miller, MD disclosed she is a member of independent data monitoring committees for Merck, Nektar and Tessaro.
Bert H. O’Neil, MD disclosed he is consultant for his role on an advisory board for Amgen, Bayer, Bristol-Myers Squibb and Celgene.  He also disclosed he received honoraria for his role on a speaker bureau with Bayer and Halozyme. 
Christopher J. Sweeney, MBBS disclosed he received honoraria for his role as a consultant from Astellas, AstraZeneca, Bayer, Genentech, Janssen, Pfizer, Roche, Sanofi and Tolmar. Continuing Nursing Education Credits
Indiana University Health is an approved provider of continuing nursing education by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91) (OH-412, 6/1/2019)7 contact hour(s) awarded by Indiana University Health. Attendance to the entire program and submission of an evaluation is necessary to receive the contact hour(s).  Continuing Pharmacy Education CreditsThis activity has been approved for 6 KNOWLEDGE BASED CE credit hours for pharmacists by Indiana University Health.  No partial credit will be given.  IU Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  (0855-9999-18-041-L01-P)

For questions about accessibility or to request accommodations please contact the CME office at 317-274-0104 or cme@iu.edu. One week advance notice will allow us to provide seamless access. Please ensure to specify the accommodations you need in order to participate.